ImmunoGen Announces Presentations at AACR Annual Meeting
March 01 2017 - 4:30PM
Business Wire
Nine presentations featuring the Company’s
leadership in ADCs
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced that nine abstracts highlighting the breath of the
Company’s expertise in ADCs will be presented at the upcoming
American Association of Cancer Research (AACR) Annual Meeting to be
held from April 1-5, 2017 in Washington D.C. The presentations at
AACR cover a wide-array of ADC innovations, including further
advancements to linkers and payloads and novel targets for both
solid tumors and hematological malignancies.
“ImmunoGen has an unmatched expertise and understanding of the
core components of ADCs and the data being presented at AACR
further validate our full-spectrum of knowledge and leadership in
this space,” said Richard Gregory, Ph.D., ImmunoGen’s chief
scientific officer. “ImmunoGen will be presenting nine abstracts at
the conference with preclinical data demonstrating technology
advances that will enable us to continue to drive innovation in ADC
approaches.”
ImmunoGen presentations at AACR relate to:
Platform linker and payload
innovations
Title: Comparison of site-specific and lysine-linked
indolino-benzodiazepine antibody-drug conjugates (ADCs) – abstract
# 75
- While site-specific conjugation can
lead to improved efficacy and tolerability, the advantages and
disadvantages of site-specific conjugation should be carefully
considered for every ADC candidate.
Title: Bystander activity and in vivo efficacy of a folate
receptor α (FRα)-targeting antibody-drug conjugate with a novel
peptide linker – abstract # 71
- Folate receptor (FRα) is an antigen
that is overexpressed on the cell surface of solid tumors including
ovarian cancer. M9346A-NL-DM is a novel ADC, employing a new
linker, with enhanced bystander activity and anti-tumor activity
that can target tumors with heterogeneous expression of FRα.
Title: Peptide-cleavable maytansinoid (ADCs) induce high
bystander killing leading to improved anti-tumor activity in vivo –
abstract # 2186
- A new promising type of maytansinoid
ADC provides a high degree of bystander killing, improved activity
in tumor models in vivo, and has a differentiated mechanism of
metabolite release.
Title: Antibody-drug conjugates (ADCs) of peptide-linked
Indolino-Benzodiazepine (IGN) DNA-alkylator provides improved
anti-tumor activity over that of a crosslinker – abstract # 53
- Preclinical research shows that
DNA-alkylating IGNs provide improved anti-tumor activity over that
of a DNA-crosslinking ADC.
Preclinical research focused on novel
targets
Title: Novel antibody-drug conjugates targeting ADAM9-expressing
solid tumors demonstrate potent preclinical activity – abstract
#37
- ADAM9 is a promising cell surface
target for antibody-drug conjugate development that is
overexpressed in multiple solid tumor indications relative to
corresponding normal tissues.
Title: Target validation, antibody discovery and preclinical
data supporting ADAM9 as an antibody-drug conjugate therapeutic
target for solid tumors – abstract #38
- These data demonstrate that anti-ADAM9
ADCs exhibit antitumor activity against a broad panel of
ADAM9-positive malignancies and cause durable remissions in
preclinical models at doses expected to be clinically achievable.
Anti-ADAM9 ADCs represent a promising therapeutic strategy to a
wide range of ADAM9-expressing tumors.
Title: In vitro and in vivo activity of a novel c-Met-targeting
antibody-drug conjugate using a DNA-alkylating,
indolinobenzodiazepine payload – abstract #45
- cMet dysregulation and/or
overexpression are associated with tumor progression, metastasis
and poor prognosis in numerous cancers. An anti-cMet antibody
conjugated with the payload DGN549 exhibits compelling, c-Met
targeted anti-cancer activity in vitro and in vivo, and represents
a promising therapeutic strategy to deliver a potent cytotoxic
agent to tumor cells bearing a wide range of c-Met expression.
Preclinical research focused on B-cell
targets
Title: A novel CD19-targeting antibody-drug conjugate,
huB4-DGN462, shows promising in vitro and in vivo activity in
CD19-positive lymphoma models – abstract #2651
- CD19 is a cell surface membrane protein
expressed in most mature and immature B cell neoplasms, which make
it a promising target for ADC therapy for B cell malignancies. A
novel CD19-targeting ADC presents strong preclinical anti-lymphoma
activity.
Title: Increased internalization and processing of the
CD37-targeting antibody-drug conjugate, naratuximab emtansine
(IMGN529), in the presence of rituximab leads to enhanced potency
in diffuse large B-cell lymphoma models – abstract #1073
- Data show enhanced activity of
rituximab plus IMGN529 combination in DLBCL models, supporting the
clinical development of this combination.
Additional information – including presentation schedule and
full abstracts – can be found at www.aacr.org.
About ImmunoGen, Inc.
ImmunoGen is a clinical-stage biotechnology company that
develops targeted cancer therapeutics using its proprietary ADC
technology. ImmunoGen's lead product candidate, mirvetuximab
soravtansine, is in a Phase 3 trial for FRα-positive
platinum-resistant ovarian cancer, and is in Phase 1b/2
testing in combination regimens for earlier-stage disease.
ImmunoGen's ADC technology is used in Roche's marketed product,
Kadcyla®, in three other clinical-stage ImmunoGen product
candidates, and in programs in development by partners Amgen,
Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda. More
information about the Company can be found at
www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of the
Roche Group.
This press release includes forward-looking statements. For
these statements, ImmunoGen claims the protection of the safe
harbor for forward-looking statements provided by the Private
Securities Litigation Reform Act of 1995. It should be noted that
there are risks and uncertainties related to the development of
novel anticancer products, including risks related to preclinical
studies and risks related to new technologies. A review of these
risks can be found in ImmunoGen's Annual Report on Form 10-K for
the fiscal year ended June 30, 2016 and other reports filed with
the Securities and Exchange Commission.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170301006328/en/
For ImmunoGen InvestorsImmunoGen, Inc.Sarah Kiely,
781-895-0600sarah.kiely@immunogen.comorFor ImmunoGen
MediaFTI Consulting, Inc.Robert Stanislaro,
212-850-5657robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Sep 2023 to Sep 2024